Actively Recruiting
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Led by University of British Columbia · Updated on 2024-12-09
100
Participants Needed
1
Research Sites
220 weeks
Total Duration
On this page
Sponsors
U
University of British Columbia
Lead Sponsor
U
University of Toronto
Collaborating Sponsor
AI-Summary
What this Trial Is About
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a "feasibility" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.
CONDITIONS
Official Title
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Meet DSM-5 criteria for major depressive disorder confirmed by clinical interview
- Currently taking a first-line antidepressant at approved doses with stable dose for at least one month
- Want to discontinue antidepressant treatment due to side effects or other reasons
- In remission with low depression scores at screening and baseline visits at least 2 weeks apart
- Able and willing to complete self-report and online assessments in English or French
You will not qualify if you...
- Any primary psychiatric diagnosis other than major depressive disorder, including bipolar I or II
- Major depressive disorder with seasonal pattern or psychotic features
- Significant personality disorder diagnosis
- High suicidal risk based on clinician judgment
- Moderate or severe alcohol or substance use disorder within past 6 months
- Significant neurological disorders, head trauma, or unstable medical conditions
- Regular use of psychotropic medication other than antidepressants or benzodiazepines (except stable ADHD stimulant use)
- History of severe antidepressant discontinuation effects
- Retinal disease or other eye conditions preventing bright light therapy
- Use of photosensitizing medication within 1 week before baseline
- Started formal psychotherapy within 3 months before study or plan to start during study
- Continued use of any other evidence-based depression treatments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Djavad Mowafaghian Centre for Brain Health
Vancouver, British Columbia, Canada, V6T 2A1
Actively Recruiting
Research Team
V
Vanessa Evans, BSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here